Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PUBLIC CITIZEN via PUBLIC CITIZEN
2026 · third_quarter · Q3
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Medicare drug price negotiation improvement and expansion; EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices; NDAA & public drug and API manufacturing,S.2276, H.R.3269 (ETHIC Act).
Medicare drug price negotiation improvement and expansion; EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices; NDAA & public drug and API manufacturing,S.2276, H.R.3269 (ETHIC Act).
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Medicare drug price negotiation improvement and expansion; EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices; NDAA & public drug and API manufacturing,S.2276, H.R.3269 (ETHIC Act).
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Pharmacists Fight Back in Medicare and Medicaid Act
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
Preserve Access to Affordable Generics and Biosimilars Act
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Preserve Access to Affordable Generics and Biosimilars Act
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Medicare drug price negotiation improvement and expansion; EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices; NDAA & public drug and API manufacturing,S.2276, H.R.3269 (ETHIC Act).
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; H.R.3269 ETHIC Act; drug prices, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276, Affordable Pricing for Taxpayer Funded Drugs Act, Medicare Part D disenrollment, Affordable Drug Manufacturing Act, End Price Gouging for Medications Act, international reference pricing,oversight of White House drug price deals, S.3822 Break Up Big Medicine Act; H.R.8779, S.4509 Patients Before Monopolies Act; H.R.6609, H.R.6610 Pharmacists Fight Back Act, pharmacy and PBM integration; WePAID Act, public drug manufacturing, HHS and Commerce prescription drug deal oversight.
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Medicare drug price negotiation improvement and expansion; EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices; NDAA & public drug and API manufacturing,S.2276, H.R.3269 (ETHIC Act).
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions, international reference pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
anti-obesity medication pricing, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth, Capping Prescription Costs Act, HHS Secretary, Deputy HHS Secretary, and CMS nominations, orphan drug exemption and negotiation delay period.H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
ORPHAN Cures Act (H.R.946; S.1862), EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions, mpox vaccine access, S.1753 End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions and international reference pricing, Medicines for the People Act, NIH intramural access planning, End Price Gouging for Medications Act; drug pricing.
anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
ORPHAN Cures Act (H.R.946; S.1862), EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions, mpox vaccine access, S.1753 End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions and international reference pricing, Medicines for the People Act, NIH intramural access planning, End Price Gouging for Medications Act; drug pricing.
anti-obesity medication pricing, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth, Capping Prescription Costs Act, HHS Secretary, Deputy HHS Secretary, and CMS nominations, orphan drug exemption and negotiation delay period.H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions, international reference pricing
H.R.3069 & S.1506 - Medicare for All, State-Based Universal Health Care Act, Patient Over Profits Act,HHS Secretary.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
ORPHAN Cures Act (H.R.946; S.1862), EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions, mpox vaccine access, S.1753 End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions and international reference pricing, Medicines for the People Act, NIH intramural access planning, End Price Gouging for Medications Act; drug pricing.
anti-obesity medication pricing, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth, Capping Prescription Costs Act, HHS Secretary, Deputy HHS Secretary, and CMS nominations, orphan drug exemption and negotiation delay period.H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions, international reference pricing
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
Preserve Access to Affordable Generics and Biosimilars Act
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
H.R.3069 & S.1506 - Medicare for All, State-Based Universal Health Care Act, Patient Over Profits Act,HHS Secretary.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
ORPHAN Cures Act (H.R.946; S.1862), EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions, mpox vaccine access, S.1753 End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions and international reference pricing, Medicines for the People Act, NIH intramural access planning, End Price Gouging for Medications Act; drug pricing.
ORPHAN Cures Act (H.R.946; S.1862), EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions, mpox vaccine access, S.1753 End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions and international reference pricing, Medicines for the People Act, NIH intramural access planning, End Price Gouging for Medications Act; drug pricing.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
anti-obesity medication pricing, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth, Capping Prescription Costs Act, HHS Secretary, Deputy HHS Secretary, and CMS nominations, orphan drug exemption and negotiation delay period.H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions, international reference pricing
ORPHAN Cures Act (H.R.946; S.1862), EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions, mpox vaccine access, S.1753 End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions and international reference pricing, Medicines for the People Act, NIH intramural access planning, End Price Gouging for Medications Act; drug pricing.
anti-obesity medication pricing, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth, Capping Prescription Costs Act, HHS Secretary, Deputy HHS Secretary, and CMS nominations, orphan drug exemption and negotiation delay period.H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.
march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.
Preserve Access to Affordable Generics and Biosimilars Act
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act.
Preserve Access to Affordable Generics and Biosimilars Act
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
Preserve Access to Affordable Generics and Biosimilars Act
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.
government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act.
Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
Affordable Prescriptions for Patients Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
Affordable Prescriptions for Patients Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.
Affordable Prescriptions for Patients Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act.
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.
Interagency Patent Coordination and Improvement Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act.
Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.
A resolution supporting the role of the United States in helping save the lives of children and protecting the health of people in low-income countries with vaccines and immunization through Gavi, the Vaccine Alliance ("Gavi").
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Drug Price Transparency in Medicaid Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Drug Price Transparency in Medicaid Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Affordable Drug Manufacturing Act, Medicare drug price negotiation implementation, reasonable pricing conditions for government-supported medical research and development; march-in and other Bayh-Dole rights, Affordable Drug Manufacturing Act; S.954 Affordable Insulin Now Act; Medicare drug price negotiation implementation, march-in rights, NIH nomination; reasonable pricing conditions for government-supported medical research and development; march-in and other Bayh-Dole rights; global licensing of government-owned medical inventions, S.79 Interagency Patent Coordination and Improvement Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act; S.142; S.150; S.148; S.1067; S.775; S.79, drug patent thicket legislation; Part D pharmacy access; ensuring accurate payments to pharmacies under Medicaid; Part D costsharing; Part D biosimilar coverage, march-in and other Bayh-Dole rights.
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Expanding Access to Low-Cost Generics Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Expanding Access to Low-Cost Generics Act of 2023
Client: PUBLIC CITIZEN · Firm: PUBLIC CITIZEN
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
PUBLIC CITIZEN via PUBLIC CITIZEN
2026 · second_quarter · Q2
S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUBLIC CITIZEN via PUBLIC CITIZEN
2026 · first_quarter · Q1
Medicare drug price negotiation improvement and expansion; EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices; NDAA & public drug and API manufacturing,S.2276, H.R.3269 (ETHIC Act).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUBLIC CITIZEN via PUBLIC CITIZEN
2025 · fourth_quarter · Q4
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
Filing targets: HOUSE OF REPRESENTATIVES, Occupational Safety & Health Administration (OSHA), SENATE, Securities & Exchange Commission (SEC)
PUBLIC CITIZEN via PUBLIC CITIZEN
2025 · third_quarter · Q3
ORPHAN Cures Act (H.R.946; S.1862), EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions, mpox vaccine access, S.1753 End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions and international reference pricing, Medicines for the People Act, NIH intramural access planning, End Price Gouging for Medications Act; drug pricing.
H.R.3069 & S.1506 - Medicare for All, State-Based Universal Health Care Act, Patient Over Profits Act,HHS Secretary.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
PUBLIC CITIZEN via PUBLIC CITIZEN
2025 · second_quarter · 2A
EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); End Price Gouging for Medications Act; Medicare drug price negotiation delay periods and exemptions, international reference pricing
Filing targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2025 · second_quarter · Q2
anti-obesity medication pricing, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth, Capping Prescription Costs Act, HHS Secretary, Deputy HHS Secretary, and CMS nominations, orphan drug exemption and negotiation delay period.H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
Filing targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Occupational Safety & Health Administration (OSHA), SENATE, Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2025 · first_quarter · Q1
anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
Filing targets: Administration for Children & Families (ACF), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Occupational Safety & Health Administration (OSHA), SENATE, Treasury, Dept of
PUBLIC CITIZEN via PUBLIC CITIZEN
2024 · fourth_quarter · Q4
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
Filing targets: General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2024 · third_quarter · Q3
government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act.
Filing targets: Consumer Financial Protection Bureau (CFPB), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Small Business Administration (SBA), Treasury, Dept of, Vice President of the U.S., White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2024 · second_quarter · Q2
Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.
Filing targets: Consumer Product Safety Commission (CPSC), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2024 · first_quarter · Q1
march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.
Filing targets: Commerce, Dept of (DOC), Federal Reserve System, General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Postal Service (USPS)
PUBLIC CITIZEN via PUBLIC CITIZEN
2023 · fourth_quarter · Q4
Affordable Drug Manufacturing Act, Medicare drug price negotiation implementation, reasonable pricing conditions for government-supported medical research and development; march-in and other Bayh-Dole rights, Affordable Drug Manufacturing Act; S.954 Affordable Insulin Now Act; Medicare drug price negotiation implementation, march-in rights, NIH nomination; reasonable pricing conditions for government-supported medical research and development; march-in and other Bayh-Dole rights; global licensing of government-owned medical inventions, S.79 Interagency Patent Coordination and Improvement Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act; S.142; S.150; S.148; S.1067; S.775; S.79, drug patent thicket legislation; Part D pharmacy access; ensuring accurate payments to pharmacies under Medicaid; Part D costsharing; Part D biosimilar coverage, march-in and other Bayh-Dole rights.
Filing targets: Commerce, Dept of (DOC), Consumer Financial Protection Bureau (CFPB), Federal Deposit Insurance Corporation (FDIC), Federal Reserve System, Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2023 · third_quarter · 3A
S.1476 Pharmaceutical Research Transparency Act, S.954 Affordable Insulin Now Act, Medicare drug price negotiation implementation; Bayh-Dole royalty-free rights and contractual reasonable pricing conditions, NDAA government owned medical invention licensing, research and development transparency, and other transactions authority justification, pay for delay reform; product hopping reform; citizen petition abuse reform; FDA prescription drug transparency, S.2220 PREVAIL Act; S. 79 Interagency Patent Coordination and Improvement Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, We PAID Act
Filing targets: Federal Deposit Insurance Corporation (FDIC), Federal Housing Finance Agency (FHFA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Credit Union Administration (NCUA), Natl Economic Council (NEC), Office of the Comptroller of the Currency (OCC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2023 · second_quarter · 2A
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2023 · third_quarter · Q3
S.1476 Pharmaceutical Research Transparency Act, S.954 Affordable Insulin Now Act, Medicare drug price negotiation implementation; Bayh-Dole royalty-free rights and contractual reasonable pricing conditions, NDAA government owned medical invention licensing, research and development transparency, and other transactions authority justification, pay for delay reform; product hopping reform; citizen petition abuse reform; FDA prescription drug transparency, S.2220 PREVAIL Act; S. 79 Interagency Patent Coordination and Improvement Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, We PAID Act
Filing targets: Federal Deposit Insurance Corporation (FDIC), Federal Housing Finance Agency (FHFA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Credit Union Administration (NCUA), Natl Economic Council (NEC), Office of the Comptroller of the Currency (OCC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2023 · second_quarter · Q2
Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2023 · first_quarter · Q1
insulin pricing; drug launch prices; access terms for medicines w/ R&D funded by USG; R&D cost transparency; alternative pharmaceutical R&D models; pandemic vaccine manufacturing, IRA implementation, telehealth and pharmaceuticals, U.S. government support for the mRNA Hub program; pandemic vaccine manufacturing, , FDA policies impacting drug prices and spending; executive licensing authorities to lower drug prices , IRA drug price negotiation implementation, IRA drug price negotiation implementation, U.S. government support for the mRNA Hub , Bayh-Dole domestic manufacturing requirements, Biosimilar Red Tape Elimination Act, executive licensing and demonstration authorities to lower drug prices; IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation; Biosimilar Red Tape Elimination Act , Prescription Drug Access and Affordability Act, Prescription Drug Price Relief Act, S.79 (Interagency Patent Coordination and Improvement Act); S.113 (Prescription Pricing for the People Act); S.142 (Preserve Access to Affordable Generics and Biosimilars Act); S.148 (Stop STALLING Act); S.150 (Affordable Prescriptions for Patients Act), S.79 (Interagency Patent Coordination and Improvement Act); S.113 (Prescription Pricing for the People Act); S.142 (Preserve Access to Affordable Generics and Biosimilars Act); S.148 (Stop STALLING Act); S.150 (Affordable Prescriptions for Patients Act; e, TRACK Act, TRACK Act, U.S. government support for the mRNA Hub program, U.S. government support for the mRNA Hub program; public vaccine manufacturing, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act; FDA-PTO coordination, covid vaccine pricing; executive licensing and demonstration authorities to lower drug prices; U.S. government support for the mRNA Hub program, insulin pricing legislation, IRA drug price negotiation implementation, IRA drug price negotiation implementation; Emergency Access to Insulin Act; S.79; S.113; S.142; S.148; S.150; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program; IRA negotiation delay periods, IRA drug price negotiation implementation; NDAA drug pricing and licensing; insulin cost & pricing legislation; S.79; S.113; S.142; S.148; S.150; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program, NDAA drug pricing, licensing and transparency requirements; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program , U.S. government support for the mRNA Hub program, executive licensing authorities to lower drug prices, Insulin for All Act; IRA drug price negotiation implementation, Insulin for All Act; IRA drug price negotiation implementation; legislation to strengthen IRA drug pricing provisions; U.S. government support for the mRNA Hub program, IRA drug price negotiation implementation, IRA drug price negotiation implementation and legislative improvements, legislation to strengthen IRA drug pricing provisions, NDAA medicines licensing, pricing and contract transparency provisions; Insulin for All Act, PASTEUR Act, Pharmaceutical Research Transparency Act; IRA drug price negotiation implementation; U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines, Protecting Consumer Access to Generic Drugs Act; U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines, U.S. government support for the mRNA Hub program; IRA drug price negotiation implementation; Emergency Access to Insulin Act, access to U.S. government funded medicines and vaccines, access to U.S. government funded medicines and vaccines, access to U.S. government funded medicines and vaccines; IRA drug price negotiation and inflationary rebate improvement legislation, access to U.S. government funded medicines and vaccines; U.S. government support for the mRNA Hub program, Affordable Insulin Now Act, Bayh-Dole march-in & royalty-free rights, Bayh-Dole march-in & royalty-free rights, IRA drug price negotiation implementation, IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines, PBM transparency Act, prescription pricing for the people act, IRA drug price negotiation implementation; IRA drug price negotiation and inflationary rebate improvement legislation, U.S. government support for the mRNA Hub program, U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines.
PUBLIC CITIZEN via PUBLIC CITIZEN
2022 · fourth_quarter · Q4
Executive Licensing authorities to lower drug prices, insulin price and out-of-pocket cost legislation (HR 3932-PASTEUR Act), Monkeypox response funding, Telehealth and Pharma advertisements, COVID-19 and monkeypox response funding, pandemic preparedness, HR 5729-Plain Prescription prices act, HR 7474/S 4037-Pharmaceutical research transparency Act, FY23 Global Health appropriations, Dr. Paul Farmer Memorial Resolution, HR 9127 (MERIT act), Non-exclusive licensing of government owned COVID technologies, Independent Drug Assessment Act, US Govt support for WHO mRNA hub initiative, expanding Medicare drug price negotiation and inflation protections, removing negotiating delay period, reforms to address product hopping, pay for delay and other monopoly issues, Pandemic vaccine funding, Alternative pharmaceutical R&D models, Patent Policy and drug pricing
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2022 · third_quarter · Q3
Drug price patent licensing executive action, INSULIN act, Licensing Government owned COVID technologies, Exercising executive licensing authorities to lower drug prices, HR 7900-NDAA amendment on Public protection of insulin for DOD, reconciliation drug price reform, and drug price negotiation provisions, Executive action to expand monkey pox Vaccine access, Global Covid 19 funding, HR 5376-Inflation reduction Act-drug pricing reform, insulin and drug price negotiation provisions, global and domestic monkey pox funding, Prescription Drugs affordability and access act, We PAID Act, USG support for mRNA hub
Filing targets: Consumer Product Safety Commission (CPSC), Federal Accounting Standards Advisory Board (FASAB), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC), White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2022 · second_quarter · Q2
HR 4502-(fy2022 Consolidated Appropriations Act), Covid-19 Vaccine manufacturing, delivery and access and related funding, S 3799 Prevent Pandemics Act (R&D Access conditions, Public MCM manufacturing, Discounted drugs for clinical Trials Act, Pharmaceutical Research and Transparency Act, Generic Substitution Non-Interference Act, drug pricing, FDA-PTO coordination, orange book reform, NDAA licensing access and drug pricing conditions, S 3700-Affordable Insulin Now Act, Drug pricing patent licensing executive Action, Compulsory licensing to lower drug prices, HR 4521-COMPETES Act mandatory drug recall authority provision, HR 7667/ S 4348-User fee legislation, advisory committee and recall provisions, NIH Director position,
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2022 · first_quarter · Q1
HR 5376-Build Back Better Act-drug pricing measures, pandemic preparedness and vaccine manufacturing, HR 6000 (CURES 2.0) antimicrobial development provisions, HR 4502-FY22 Consolidated Appropriations Act-Covid-19 vaccine manufacturing, Affordable Insulin NOW Act, Discounted drugs for clinical trials act, Pharmaceutical Research and transparency, S 2891-Restoring the America Invents Act, HR 4521-America COMPETES act, Plain prescription Prices act, S 3799-PREVENT Pandemics Act, COVID 19 vaccine manufacturing and delivery.
Filing targets: Consumer Financial Protection Bureau (CFPB), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), Office of Special Counsel, Office of the Comptroller of the Currency (OCC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2021 · fourth_quarter · Q4
Build back better act-drug pricing measures, HR 3778/S 1976 (NOVID Act)-Covid-19 Vaccine manufacturing and access and related funding, HR 5376-Pandemic preparedness and drug pricing measures,
Filing targets: Consumer Financial Protection Bureau (CFPB), Education, Dept of, Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), Office of Government Ethics (OGE), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Postal Service (USPS), White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2021 · third_quarter · Q3
HR3778/S 1976 (NOVID Act); Covid-19 Vaccine manufacturing and access and related funding, HR 3 (Lower Drug Costs Now Act, Senate Finance Drug price reform package, Aducanumab, Drug pricing, Insulin affordability for all Act, Medicare Negotiation and Competitive Licensing Act, We PAID Act, S. 1435-Affordable Prescriptions for Patients Act, Vaccine manufacturing and NDAA
Filing targets: Consumer Product Safety Commission (CPSC), Equal Employment Opportunity Commission (EEOC), Federal Accounting Standards Advisory Board (FASAB), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE, Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2021 · second_quarter · Q2
Covid-19 Vaccine Manufacturing and access and related funding, drug price negotiation, FAIR drug pricing Act, clinical trial cost transparency, HR 3 Lower drug prices now act, HR 2096-SACKLER Act, Affordable medications act, prescription drug price spike remedies, Medical Innovation act, National Biomedical research act, USTR access to medicines position, HR 3778/S 1976 (NOVID act), Aducanumab, S.1435-Affordable Prescriptions for Patients act,
Filing targets: Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Occupational Safety & Health Administration (OSHA), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2021 · first_quarter · Q1
Covid-19 medicine pricing and access, drug price negotiation, biologics exclusivity, NIST legislative package, Pandemic treatment access and affordability act, Pandemic emergency Manufacturing Act, Medicare and Medicaid prescription drug rebates, We PAID act, Empowering Medicare seniors to Negotiate drug Pricing act, global COVID 19 vaccine access, Stop Stalling act, drug price spike excise act, repealing direct to consumer advertisement tax, Stop Price Gouging Act, Preserving access to affordable generics, TRACK act, drug R&D cost transparency, using executive authority to increase vaccine production.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2020 · third_quarter · 3A
H.R. 7296 (MMAPPP Act); H.R. 7288 (TRACK Act); Patents for Humanity Program Improvement Act; transparency for federally support covid R&D; covid-19 medicine pricing and access, Drug pricing, Covid 19 Medicine pricing, manufacture and access,
Assisted living Facilities legislation, HR 1384/S 1804-Medicare for all Act, Covid 19-response package/surprise billing,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
PUBLIC CITIZEN via PUBLIC CITIZEN
2020 · third_quarter · 3A
H.R. 7296 (MMAPPP Act); H.R. 7288 (TRACK Act); Patents for Humanity Program Improvement Act; transparency for federally support covid R&D; covid-19 medicine pricing and access, Drug pricing, Covid 19 Medicine pricing, manufacture and access,
Assisted living Facilities legislation, HR 1384/S 1804-Medicare for all Act, Covid 19-response package/surprise billing,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
PUBLIC CITIZEN via PUBLIC CITIZEN
2020 · fourth_quarter · Q4
Medicare drug price regulation, HR 7296/S 4439 (MMAAPP Act), HR 7288/S 4539 (TRACK Act), transparency for federally support COVID R&D,COVID-19 Medicine pricing and access, HR 4663-Freedom from Price Gouging Act, HR 1093/S 378-Stop Price Gouging Act, S 3847/HR 7113 (COVID 19 Emergency Manufacturing Act, CARES 2.0-S.1712/HR4100-DISARM Act, S 4760-PASTEUR Act, Antibiotic drug development, Prescription drug transparency, S 1416/HR 5133, S-64,HR-2374,HR-3379-Pharma competition legislation, Medicare Part B drug reimbursement
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2020 · third_quarter · Q3
H.R. 7296 (MMAPPP Act); H.R. 7288 (TRACK Act); Patents for Humanity Program Improvement Act; transparency for federally support covid R&D; covid-19 medicine pricing and access, Drug pricing, Covid 19 Medicine pricing, manufacture and access,
Assisted living Facilities legislation, HR 1384/S 1804-Medicare for all Act, Covid 19-response package/surprise billing,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
PUBLIC CITIZEN via PUBLIC CITIZEN
2020 · second_quarter · Q2
Access to coronavirus treatments and vaccines, COVID-19 medicine pricing and access, COVID-19 Emergency manufacturing act, transparency for federally support COVID R&D, Pharmaceuticals and antitrust
Filing targets: Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2020 · first_quarter · Q1
Drug Pricing, HR 2375, S 64-Preserve Access to Affordable Generics and Biosimilars Act) HR 2374/S 1224 Stop STALLING act, HR 2387-Stop GAMES act, S. 1416/HR 5133-Affordable Prescriptions for Patients Act, S2543-Prescription Drug Pricing Reduction Act, S 551-Refund Act, Coronavirus, Coronavirus Preparedness and Response Supplemental Appropriations Act (HR 6074), HR3/S 3166-Lower Drug costs now act, HR 1093/S 378-Stop Price Gouging Act, S 377/HR 1046-Medicare Negotiation and Competitive Licensing Act, H 1801-Affordable Medications Act
Filing targets: Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC)
PUBLIC CITIZEN via PUBLIC CITIZEN
2019 · fourth_quarter · Q4
HR 3/S 2543-Prescription Drug Affordability and access act, Drug Pricing, HR 965/S 340 (CREATES; Act), HR 2375/S 64-Preserve access to affordable generics and biosimilars act, S 1416-Affordable Prescriptions for Patients Act, HR 2374/S 1224-Stop Stalling Act, HR 1046-Medicare Negotiation and Competitive Licensing Act, HR 3815-PREP access and coverage act, S 2387-We PAID act, HR 3199-TERM act, HR 5133-Affordable Prescriptions for Patients through providing competition act, Affordable drug manufacturing act
Filing targets: Consumer Product Safety Commission (CPSC), Federal Energy Regulatory Commission (FERC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
PUBLIC CITIZEN via PUBLIC CITIZEN
2019 · third_quarter · Q3
HR 1046, S 377-Medicare Negotiation and Competitive Licensing Act, S 1987-End Price Gouging for Medications act, HR 3199-TERM Act, S 1895-Lower Health Care Costs Act, S 1209-(REMEDY act), S 1416-Affordable Prescriptions for Patients Act, HR 2374, S 1224-Stop STALLING Act, HR 3379-PRICED Act, HR 2296, S 1391-(FAIR Drug Pricing Act), drug pricing, HR 2296-METRIC Act, S 2004-Emergency Access to Insulin Act, S 2387-We protect American Investments in Drugs Act (We PAID Act), S 2199-Insulin Price Reduction Act, S 977-Transparent Drug Prices Act, S 378-Stop Price Gouging Act, S 340-CREATES Act, HR 3- Patient Advocacy Transparency Act,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2019 · second_quarter · Q2
HR 1046/S 377-Medicare negotiation and competitive licensing act, HR 938-BLOCKING ACT, hr 965/s340- (creates ACT), HR 1503-Orange book transparency act, HR 1520-Purple book continuity act, HR 1499-Protecting consumer access to generic drugs act, S 64-preserve access to affordable generics and biosimilars act, drug pricing, HR 2113-Prescription drug STAR act, HR 1093/S 378 (Stop price gouging act, HR 1344-Competitive drugs act, HR 465/S 102-Prescription drug price relief act, HR-3379- PRICED act, affordable drug manufacturing act, S 1416-Affordable prescriptions to patients act, HR 2374/S 1224 (stop STALLING act) HR 2917 Opioid Crisis accountability act, S 1209-REMEDY ACT, hr 6505 Medicare Negotiation and competitive Licensing act, SEC 101-Patent reform legislation
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2019 · first_quarter · Q1
HR 1046/S 377-Medicare Negotiation and Competitive Licensing Act, Drug Pricing, HR 965-CREATES Act, Medicare for all Act, S 378/HR 1093-Stop price gouging Act, HR 985-Fast Generics act, HR 1499-Protecting consumer access to generic drugs act, HR 1506-FAIR generics act,
NAFTA renegotiation, USMCA,drug pricing,
HR 1384-Medicare for All,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2018 · fourth_quarter · Q4
HR 6505-Medicare Negotiation and competitive licensing act, S 1369/HR 2974-Stop price gouging Act, HR 6577-PRICED Act, S 124-Preserve access to affordable generics act, HR 4117-competitive drugs act, S 974/HR 2212-CREATES act, drug pricing, HR 4116-Transparent drug pricing act, HR 1776-Improving access to affordable prescription drugs act, S 3680-Low Drug Prices act, HR 676-Expanded and Improved Medicare for all act, S 3775-Affordable drug manufacturing act,
NAFTA renegotiation, United States, Mexico, and Canada Trade agreement-drug pricing
Filing targets: Commodity Futures Trading Commission (CFTC), Federal Deposit Insurance Corporation (FDIC), Federal Reserve System, HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2018 · third_quarter · Q3
S. 2852/HR 3678-Pandemic and all-hazards preparedness and advancing innovation act of 2018, HR 6294-REVAMP Act, Medicare Part D negotiation, prescription drug pricing, HR 6505-Medicare negotiation and competitive licensing act, HR 6577-PRICED act, HR 6576-Drug Price Transparency in Communications act, medicare prescription drug savings and choice act, HR 1223/S 1509 OPEN Act, S 1369-Stop Price gouging act.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Government Ethics (OGE), SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2018 · second_quarter · Q2
S 2011/HR 4138-Medicare Drug Price Negotiation Act, S 974/HR 2212-CREATES Act of 2017, S 124-Preserve Access to Affordable Generics Act, HR 1625-OMNIBUS, opioid addiction data analysis, S 771-Improving access to affordable prescription drugs act, S 252-Medicare Drug Savings act of 2017, S 1369-Stop Price Gouging Act, S 495-Medical innovation and prize fund act, S 1131/HR 2439-FAIR drug pricing act, HR 4117-Competitive Drugs act of 2017, S 771/HR 1776-Improving access to affordable prescription drugs act, S 637-C-THRU Act, S 1347-RxCap Act of 2017, S 1348-SPIKE Act of 2017, HR 5156-Protecting Medicare from Excessive Price Increases Act of 2018, S 2691-Opioid Crisis accountability act of 2018, S 2315-Over the counter drug safety, innovation, and reform act, S 2700/HR 5545-Comprehensive Addiction Resources Emergency (CARE) act, Drug Pricing-Medicare Part D HR 2051-FAST Generics Act of 2017, HR 4116-Transparent Drug Pricing Act, S 2852-Pandemic and All-Hazards Preparedness Act and advancing innovative Act of 2018,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2018 · first_quarter · Q1
S. 771/HR 1776-Improving access to affordable Prescription Drugs act, S 2157-Drug Price transparency in Communications Act, S 2011/HR 4138-Medicare drug price negotiation act of 2017, S 1688-Empowering medicare seniors to negotiate drug prices of 2017, S 252-Medicare drug savings act of 2017, S 1369/HR 2974-Stop Price gouging act, S 124-Preserve access to affordable generics act, S 974/HR 2212-CREATES Act of 2017, S 495-Medical Innovation and Prize Fund Act, S 1131/HR 2439-FAIR drug pricing act, Over-the-counter Monograph Safety, Innovation, and Reform Act of 2018, HR 4117-Competitive DRUGS Act of 2017), HR 2051- FAST Generics Act of 2017), Prescription drug pricing, PACED Act, S 771/HR 1776 (Improving access to affordable prescription drugs act, S 1509/HR 1223 OPEN Act), S 1309-Stronger patents act, HR 5150 Protecting Medicare from excessive price increases act, S 2476-Expanding access to low cost generics act, S 637 (c-thru act), S 1348-SPIKE act,
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2017 · fourth_quarter · Q4
S 771/HR1776-Improving access to affordable prescription drugs act, S 2011/HR 4138-Medicare Price Negotiation Act of 2017, S 252-Medicare Drug Savings Act of 2017, S 1369/HR 2974-Stop Price Gouging Act, S 124-Preserve access to affordable generics act, HR 4117-Competitive DRUGS Act of 2017, S 974/HR 2212-CREATES act of 2017, HR 2051-FAST generics Act of 2017, S 495-Medicare Innovation Prize Fund Act, S 1131.HR 2439-FAIR Drug Pricing act, HR 4116-Transparent Drug Pricing Act of 2017, S 1509-Orphan Products extension accelerating cures and treatments, HR 1223-OPEN act, S 1390-Stronger Patriots Act of 2017, S 1827-KIDS Act of 2017, HR 1628-American Health care act of 2017, HR 3921-Healthy KIDS Act, HR 4116-Transparent drug pricing act of 2017, Bipartisan Health Care Stabilization Act of 2017, biologic market exclusivity, inter partes review, direct to consumer advertising, Over-the-counter Monograph Safety Innovation and Reform act of 2017, Azar HHS nomination,
Filing targets: Agriculture, Dept of (USDA), Education, Dept of, Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Office of Government Ethics (OGE), SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR), White House Office
PUBLIC CITIZEN via PUBLIC CITIZEN
2017 · third_quarter · Q3
S 934/HR 2430-FDA re-authorization Act of 2017, S 974/HR 2212-CREATES Act, S 771/HR 1776-Improving access to affordable prescription drugs act, S 204-Trickett Wendler Right to try act of 2017, S 1509/HR 1223-OPEN act, S 1369/HR 2974-Stop Price Gouging Act, Preserve access to affordable generics act, HR 205-to amend the Food, Drug & Cosmetic Act to require labeling of genetically engineered fish, S 495-Medicaid Innovation Price Fund Act, S 252-Medicaid Drug Savings Act of 2017,S 1131/HR 2439-Fair Accountability and Innovative Research Drug Pricing Act of 2017, HR 1628-American Health Care Act of 2017, S 297-Increasing Competition in Pharmaceuticals Act, HR 749 Lower drugs through Competition act, S 1390-stronger patents act of 2017, S 168/HR 3536-A bill to require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements with Secretary of HHS.
Filing targets: Consumer Product Safety Commission (CPSC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
PUBLIC CITIZEN via PUBLIC CITIZEN
2017 · second_quarter · 2A
S 297-Increased competition in Pharmaceuticals Act, HR 1703-Medical Prudent Communications Act of 2017, HR 2026- Pharmaceutical Information Exchange Act, S-252-Medicare Drug Savings act of 2017, Right to try legislation, Prescription Drug Importation, and HR 1223-OPEN Act.
Protect the CMS Nursing Home Arbitration Regulation from rollback, Single-payer health care legislation, Improving Access to Affordable Prescription Drugs Act (S.771 and HR 1776), Stop Price Gouging Act (S 1369/HR 2974), FAIR Drug Pricing act (S. 1131 and HR 2439), American Health Care Act (HR 1628), CREATES Act (S 974/HR 2212), FAST Generics Act (HR 2841), FDA Reauthorization Act of 2017 (S 934, HR 2430), Preserve Access to Affordable Generics Act (S 124).
Filing targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Consumer Financial Protection Bureau (CFPB), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Occupational Safety & Health Administration (OSHA), SENATE, Treasury, Dept of, U.S. Agency for International Development (USAID), White House Office